Neurogene Reports $20.9 Million Net Loss in Q3 2025, No Revenue Generated

Neurogene Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $20.9 million, compared to a loss of $20.2 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $65.6 million, up from $55.6 million in the prior year. The increase in losses is attributed to rising operating expenses, which totaled $23.8 million for the quarter and $75.8 million for the nine-month period, reflecting a year-over-year increase of 7.3% and 22.2%, respectively. Notably, the company did not generate any revenue during the quarter or the nine-month period, a decline from $0.9 million in licensing revenue reported for the same nine months in 2024.

Research and development expenses rose to $17.2 million for the third quarter, up from $16.3 million in the prior year, driven primarily by increased costs associated with the ongoing clinical trials for its lead product, NGN-401, aimed at treating Rett syndrome. General and administrative expenses also increased, totaling $6.6 million for the quarter, compared to $5.9 million in the same period last year, largely due to higher personnel costs and stock-based compensation. The company’s accumulated deficit reached $327.9 million as of September 30, 2025.

In terms of operational developments, Neurogene has made significant strides in its clinical programs. The company is advancing its NGN-401 program, which is currently in a registrational trial known as Embolden, targeting a patient population with high unmet needs. The trial is designed to evaluate the efficacy of NGN-401 in females with Rett syndrome, with the first participant dosed in the fourth quarter of 2025. The company has also established a fully operational cGMP manufacturing facility in Houston, Texas, which is expected to enhance its product development capabilities.

As of September 30, 2025, Neurogene had cash, cash equivalents, and short-term investments totaling approximately $265.4 million, a decrease from $335.7 million at the end of 2024. The company anticipates that its existing capital will be sufficient to fund operations for at least the next year. However, management has indicated that additional capital will be necessary to support ongoing clinical trials and operational expenses. The company plans to pursue various financing options, including equity or debt financing, to ensure continued operations and development of its product candidates.

Looking ahead, Neurogene remains focused on advancing its clinical programs and expanding its product pipeline. The company is committed to addressing the challenges of neurological diseases through its proprietary gene therapy technology. However, it acknowledges the inherent risks and uncertainties in the biotechnology sector, including the need for successful clinical outcomes and regulatory approvals, which will be critical for future revenue generation and overall business sustainability.